bioAffinity Technologies Hits 52-Week Low at $2.27 Amidst 94% Decline

bioAffinity Technologies, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 2.27 as of November 3, 2025. This significant decline highlights the company's ongoing struggles in a competitive market. Over the past year, bioAffinity has experienced a stark return of -94.29%, contrasting sharply with the S&P 500's performance of 19.89%.
The company's financial metrics reveal a challenging landscape. With a market capitalization of just USD 7 million, bioAffinity is classified as a microcap stock. It has reported an operating loss, with net sales growing at an annual rate of 105.51% but accompanied by an operating profit decline of -223.18% over the last five years. The company's debt equity ratio stands at 0.19, indicating a relatively low level of debt, yet its ability to service this debt remains weak, as evidenced by a poor EBIT to interest ratio of -5.67.

Additionally, bioAffinity's return on equity is notably high at 497.45%, but this figure is overshadowed by negative operating cash flow of USD -7.68 million. The stock's price-to-book ratio of -3.27 further underscores the challenges it faces. Overall, bioAffinity Technologies, Inc. is navigating a difficult period marked by significant financial hurdles and underperformance relative to broader market indices.